Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; erythrosine; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; purified talc; sodium lauryl sulfate; purified water; gelatin; titanium dioxide; brilliant blue fcf - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: brilliant blue fcf; pregelatinised maize starch; gelatin; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; purified talc; lactose monohydrate; purified water; titanium dioxide - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; erythrosine; titanium dioxide; lactose monohydrate; brilliant blue fcf; purified water; sodium lauryl sulfate; gelatin - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. with three episodes in two years, there is no doubt it should be given. as a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. a major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. for these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.

Australia - English - Department of Health (Therapeutic Goods Administration)

nice-pak products pty ltd - menthol, quantity: 1.2 mg/cm2; methyl salicylate, quantity: 1.32 mg/cm2; camphor, quantity: 260 microgram/cm2; dl-alpha-tocopheryl acetate, quantity: 24 microgram/cm2; thymol, quantity: 168 microgram/cm2; hydroxyethyl salicylate, quantity: 200 microgram/cm2 - patch, dermal - excipient ingredients: - this product accepted for registration/listing as ?currently supplied? at the time of commencement of the act. indications at the time of grandfathering: use as an aid in the treatment of stiff shoulder, lumbago, muscular pains, muscular fatigue, bruising, sprains, neuralgia, rheumatism, joint pains, headache and toothache

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aspirin, quantity: 25 mg; dipyridamole, quantity: 200 mg - capsule, modified release - excipient ingredients: hypromellose phthalate; gelatin; methacrylic acid copolymer; microcrystalline cellulose; tartaric acid; purified talc; pregelatinised maize starch; sucrose; hypromellose; triacetin; acacia; stearic acid; iron oxide red; iron oxide yellow; titanium dioxide; povidone; sodium benzoate; potable water; simethicone; cetostearyl alcohol - for the prevention of recurrent ischaemic stroke and transient ischaemic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - chlorantraniliprole; thiamethoxam - water dispersible granule - chlorantraniliprole benzene active 200.0 g/kg; thiamethoxam thiazole active 200.0 g/kg - insecticide - cotton - brokenbacked bug | cotton aphid | cotton budworm or bollworm | green mirid bug | green peach aphid | native budworm or bollworm | vegetable leafhopper | yellow mirid | apple dimpling bug | brokenback bug | corn earworm | cotton bollworm | dimpling bug | heliothis | melon aphid | native bollworm | taylorilygus apicalis | tobacco budworm | tomato grub | vegetable jassid